Sign inJoin waitlistJoin the waitlist

Enrique Alvarez

Vice Chair - Clinical Research · University of Colorado School of Medicine

Credentials: · · · · ·

History

University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present

Washington University School of Medicine
2012–2013
Neurology
Washington University/B-JH/SLCH Consortium
2006–2010
Internal Medicine
Washington University School of Medicine
2007–2010
University of Colorado School of Medicine
2002–2006
North Dakota State University
1998–2002

Research

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
New England Journal of Medicine · 2018 · 231 citations
A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat
Journal of Neuroscience · 2002 · 210 citations
Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis
Archives of Neurology · 2011 · 209 citations

KN
Kavita Nair
20 papers
John Corboy
19 papers
TV
Timothy Vollmer
18 papers
Anne Cross
11 papers
RN
Robert Naismith
9 papers
Andrew Wolf
8 papers · 5 as a resident
EF
Edward Fox
8 papers
Andrew Solomon
7 papers
Daniel Ontaneda
7 papers
SW
Sibyl Wray
7 papers
Amanda Piquet
6 papers · 2 as a resident
Derrick Robertson
6 papers

Clinical trials

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Principal investigator · Recruiting · Phase 4
University of Colorado, Denver
2024–2029
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)
Principal investigator · Active not recruiting
University of Colorado, Denver
2023–2026
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
Principal investigator · Completed · Phase 3
University of Colorado, Denver
2017–2019
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2034